Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106


Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adults.

Polishchuk AL, Dubois SG, Haas-Kogan D, Hawkins R, Matthay KK.

Cancer. 2011 Sep 15;117(18):4286-93. doi: 10.1002/cncr.25987.


Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.

J Clin Oncol. 2007 Mar 20;25(9):1054-60.


Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.

Modak S, Zanzonico P, Carrasquillo JA, Kushner BH, Kramer K, Cheung NK, Larson SM, Pandit-Taskar N.

J Nucl Med. 2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752.


Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).

Zhou MJ, Doral MY, DuBois SG, Villablanca JG, Yanik GA, Matthay KK.

Eur J Cancer. 2015 Nov;51(16):2465-72. doi: 10.1016/j.ejca.2015.07.023.


Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.

Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J.

J Nucl Med. 2012 Jul;53(7):1155-63. doi: 10.2967/jnumed.111.098624. Erratum in: J Nucl Med. 2016 Jun;57(6):988.


Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.

Kang TI, Brophy P, Hickeson M, Heyman S, Evans AE, Charron M, Maris JM.

J Pediatr Hematol Oncol. 2003 Oct;25(10):769-73.


[Radio iodized metaiodobenzylguanidine (MIBG) in the treatment of neuroblastoma: modalities and indications].

Défachelles AS, Cougnenc O, Carpentier P.

Bull Cancer. 2011 May;98(5):559-69. doi: 10.1684/bdc.2011.1353. Review. French.


Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma.

Matthay KK, DeSantes K, Hasegawa B, Huberty J, Hattner RS, Ablin A, Reynolds CP, Seeger RC, Weinberg VK, Price D.

J Clin Oncol. 1998 Jan;16(1):229-36.


Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

DuBois SG, Matthay KK.

Nucl Med Biol. 2008 Aug;35 Suppl 1:S35-48. doi: 10.1016/j.nucmedbio.2008.05.002. Review.


Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.

Matthay KK, Panina C, Huberty J, Price D, Glidden DV, Tang HR, Hawkins RA, Veatch J, Hasegawa B.

J Nucl Med. 2001 Nov;42(11):1713-21.


131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.

French S, DuBois SG, Horn B, Granger M, Hawkins R, Pass A, Plummer E, Matthay K.

Pediatr Blood Cancer. 2013 May;60(5):879-84. doi: 10.1002/pbc.24351.


Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).

Trieu M, DuBois SG, Pon E, Nardo L, Hawkins RA, Marachelian A, Twist CJ, Park JR, Matthay KK.

Pediatr Blood Cancer. 2016 Mar;63(3):436-42. doi: 10.1002/pbc.25816.


Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine.

Garaventa A, Gambini C, Villavecchia G, Di Cataldo A, Bertolazzi L, Pizzitola MR, De Bernardi B, Haupt R.

Cancer. 2003 Mar 1;97(5):1332-8.


Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.

Bleeker G, Schoot RA, Caron HN, de Kraker J, Hoefnagel CA, van Eck BL, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(11):1711-7. doi: 10.1007/s00259-013-2510-z.


Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma.

Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK.

Pediatr Blood Cancer. 2011 Feb;56(2):191-201. doi: 10.1002/pbc.22767.


Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study.

Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM.

J Clin Oncol. 2009 Mar 1;27(7):1020-5. doi: 10.1200/JCO.2007.15.7628.


Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.

DuBois SG, Messina J, Maris JM, Huberty J, Glidden DV, Veatch J, Charron M, Hawkins R, Matthay KK.

J Clin Oncol. 2004 Jun 15;22(12):2452-60.


The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma.

Schoot RA, Bleeker G, Caron HN, van Eck BL, Heij HA, de Kraker J, Tytgat GA.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1516-22. doi: 10.1007/s00259-013-2455-2.


Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

Matthay KK, Tan JC, Villablanca JG, Yanik GA, Veatch J, Franc B, Twomey E, Horn B, Reynolds CP, Groshen S, Seeger RC, Maris JM.

J Clin Oncol. 2006 Jan 20;24(3):500-6.

Items per page

Supplemental Content

Support Center